How to Remove Belly Fat: NHS-Backed Advice

How to remove belly fat is one of the most searched health questions in the UK, and for good reason: excess abdominal fat is not simply a cosmetic concern but a genuine clinical risk factor for type 2 diabetes, cardiovascular disease and other serious conditions. This article explains why belly fat is particularly stubborn, what the NHS and NICE recommend for losing it safely, how diet and exercise compare, when medication may be appropriate, and how long realistic results take. Whether you are just starting out or have already tried lifestyle changes without success, this guide covers the evidence-based options available in the UK.

Why is belly fat so hard to lose, and is it actually dangerous?

Belly fat is hard to lose because much of it is visceral fat regulated by hormones such as cortisol and insulin. A waist above 94 cm in men or 80 cm in women signals increased health risk, including for type 2 diabetes and cardiovascular disease.

Belly fat is particularly difficult to lose because a significant proportion of it is visceral fat, a metabolically active type stored deep within the abdominal cavity around the organs. Visceral fat is regulated by hormones including cortisol and insulin, and stress, poor sleep and blood sugar fluctuations can all influence fat distribution and eating behaviours in ways that promote its accumulation, alongside overall calorie intake.

Visceral fat is clinically significant. NHS guidance identifies a waist circumference above 94 cm (37 inches) in men and above 80 cm (31.5 inches) in women as a marker of increased health risk, with thresholds above 102 cm and 88 cm respectively indicating substantially higher risk. For some South Asian, Chinese and other ethnic groups, health risks associated with central adiposity occur at lower waist measurements, and the NHS and NICE recommend using lower thresholds for these populations. Excess visceral fat is associated with type 2 diabetes, cardiovascular disease, high blood pressure and certain cancers.^[1][6]

Genetics also play a role. Some people are predisposed to store fat centrally rather than on the hips or thighs, a pattern sometimes called android or apple-shaped obesity. Hormonal changes, particularly the decline in oestrogen during the menopause, can shift fat distribution towards the abdomen in women. These biological factors explain why targeted abdominal exercises alone cannot remove belly fat: fat loss is a whole-body process. Encouragingly, research suggests that visceral fat often responds relatively early to lifestyle changes, meaning internal health improvements can begin before visible changes around the waist become apparent, though the rate of change varies between individuals.

What does the NHS recommend for losing belly fat safely?

The NHS recommends a calorie-controlled diet based on the Eatwell Guide combined with at least 150 minutes of moderate aerobic activity per week, plus muscle-strengthening exercise on two or more days.

The NHS recommends a combination of a balanced, calorie-controlled diet and regular physical activity as the foundation for reducing belly fat safely and sustainably. There is no NHS-endorsed shortcut, and the guidance is consistent with NICE clinical guidelines on obesity management, which emphasise lifestyle intervention as the first-line approach for most adults.

For physical activity, the UK Chief Medical Officers' guidelines, summarised on the NHS website, advise adults to aim for at least 150 minutes of moderate-intensity aerobic activity per week, such as brisk walking, cycling or swimming, alongside muscle-strengthening activities on two or more days per week. Both types of exercise contribute to reducing visceral fat over time.

For diet, the NHS Eatwell Guide recommends basing meals on starchy carbohydrates, eating plenty of fruit and vegetables, choosing lean proteins, limiting saturated fat and free sugars, and reducing salt intake. Reducing sugary drinks and ultra-processed foods is associated with better weight and metabolic outcomes, and limiting these is a practical step for most people trying to reduce abdominal fat.

The NHS also highlights the importance of sleep and stress management. Chronic sleep deprivation raises cortisol levels, which can influence fat storage and appetite. The NHS advises that most adults need around six to nine hours of sleep per night.^[3][4] Alcohol reduction is another practical step: alcohol is calorie-dense and is associated with central fat deposition, which is why excess intake is linked to the term "beer belly". If you are concerned about your waist measurement or overall weight, speaking to your GP is a sensible starting point for personalised advice.

Do diet changes or exercise work better for reducing belly fat?

Diet has a greater impact on overall fat loss by creating a calorie deficit, while aerobic exercise is particularly effective at reducing visceral fat. Combining both produces the best and most sustainable results.

Diet changes and exercise both reduce belly fat, but the evidence consistently shows that dietary modification has a greater impact on overall fat loss, while aerobic exercise can be particularly effective at reducing visceral fat. The most effective approach combines both, as they work through complementary mechanisms.

Calorie restriction creates the energy deficit needed for fat loss across the body, including the abdomen. Research, including systematic reviews and meta-analyses, suggests that Mediterranean-style and lower-carbohydrate diets may be associated with reductions in visceral fat, though total calorie intake remains the primary driver and results vary between individuals and populations.^[24][25] Reducing refined carbohydrates and added sugars is relevant because these foods can drive insulin secretion and contribute to overall energy surplus, which over time may promote fat storage.

Aerobic exercise, even without large amounts of weight loss, has been shown in systematic reviews to reduce visceral fat, likely through improvements in insulin sensitivity and metabolic function.^[20][21] Resistance training helps preserve lean muscle mass during weight loss, which supports long-term weight management, though the effect on resting metabolic rate is generally modest.

Key practical points:

• Prioritise diet for creating a calorie deficit and reducing visceral fat drivers such as refined sugar and alcohol.

• Add aerobic exercise (brisk walking, jogging, cycling) for direct visceral fat reduction.

• Include resistance training to preserve muscle mass during weight loss.

• Avoid spot-reduction myths: no exercise targets abdominal fat in isolation.

Combining moderate dietary changes with consistent physical activity is more sustainable than extreme restriction, and sustainability is what determines long-term results around the waist.

Can medication or medical treatment help if lifestyle changes aren't enough?

MHRA-authorised medicines including tirzepatide (Mounjaro), semaglutide (Wegovy) and orlistat are available as adjuncts to lifestyle changes for adults meeting NICE BMI and comorbidity criteria.

Medication can be an appropriate option for adults who have not achieved sufficient results through lifestyle changes alone, provided they meet specific clinical criteria. NICE guidance recommends weight management medicines as an adjunct to, not a replacement for, diet and physical activity.

Currently MHRA-authorised medicines for chronic weight management in the UK include:

• Orlistat (Xenical, Alli): a lipase inhibitor that reduces dietary fat absorption in the gut, available on prescription and in a lower dose over the counter.^[17][18]

• Semaglutide injection (Wegovy): a GLP-1 receptor agonist given as a weekly subcutaneous injection, authorised for adults with a BMI of 30 kg/m2 or above, or 27 kg/m2 or above with at least one weight-related comorbidity. Wegovy is available in doses up to 2.4 mg weekly, with a higher 7.2 mg strength also authorised by the MHRA.

• Oral semaglutide (Wegovy 25 mg tablets): an oral GLP-1 receptor agonist for weight management, MHRA-authorised in June 2026, with a different posology from the injection.^[12] A prescriber can advise on suitability.

• Tirzepatide (Mounjaro): a dual GIP and GLP-1 receptor agonist, authorised in the UK for both type 2 diabetes and chronic weight management. It is administered as a weekly injection using a multiple-dose KwikPen.

• Liraglutide (Saxenda): a daily GLP-1 receptor agonist injection for weight management.

• Orforglipron (Foundayo): an oral GLP-1 receptor agonist authorised in the UK for weight management.^[15][16] A prescriber can advise on eligibility and dosing.

Orlistat works by reducing dietary fat absorption. The GLP-1 and dual GIP/GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide, orforglipron) work by reducing appetite, slowing gastric emptying and improving metabolic signalling, which together support a calorie deficit and reduce visceral fat over time.

These medicines are not suitable for everyone, including during pregnancy or breastfeeding, and a prescriber must assess eligibility based on BMI, comorbidities, contraindications and medical history. If you experience suspected side effects from any of these medicines, you can report them via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk.

NHS access to these medicines depends not only on meeting NICE criteria but also on local commissioning arrangements, Integrated Care Board (ICB) policies and availability through specialist tiered weight-management services. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where Mounjaro is one option a prescriber may consider if it is clinically appropriate.

Bariatric surgery is considered for people with severe obesity where other interventions have not been effective. Referral is made through NHS pathways, and access depends on NICE criteria as well as local ICB commissioning decisions and specialist service availability.

How long does it realistically take to see results around your waist?

Most people see measurable waist reductions within three to six months at the NHS-recommended rate of 0.5 to 1 kg per week. Waist circumference is a more reliable indicator of visceral fat loss than weight alone.

Most people begin to notice measurable reductions in waist circumference within the first few months of consistently following a calorie-controlled diet combined with regular aerobic exercise, though the rate of change varies considerably between individuals. As noted earlier, visceral fat often responds relatively early to lifestyle changes, meaning internal health improvements may begin before visible changes around the waist become apparent.

A realistic and sustainable rate of weight loss is generally considered to be 0.5 to 1 kg per week, in line with NHS guidance. At this rate, meaningful reductions in waist circumference can be expected over a period of three to six months. Faster loss is possible in the early weeks, partly due to reductions in glycogen stores and associated water retention, but this initial phase should not be mistaken for the longer-term rate of fat loss.

For people using MHRA-authorised weight management medicines, clinical trial data (including the STEP and SURMOUNT trial programmes for semaglutide and tirzepatide respectively) show that significant reductions in body weight and waist circumference typically emerge over the first few months of treatment, with continued improvement over the full treatment period of up to a year or more. Results depend on adherence to both the medication and the accompanying lifestyle programme.

Important points to keep in mind:

• Waist measurement is a more useful indicator of visceral fat reduction than weight alone.

• Plateaus are normal: the body adapts to a calorie deficit over time, and adjustments to diet or activity may be needed.

• Consistency matters more than speed: sustainable habits produce lasting results.

• Speak to your GP if you are not seeing any change after three months of genuine lifestyle effort, as underlying conditions such as hypothyroidism or polycystic ovary syndrome can impair fat loss and warrant investigation.

Scientific References

1. Overweight and obesity in adults.
2. Physical activity guidelines for adults aged 19 to 64.
3. Sleep problems – Every Mind Matters.
4. Insomnia.
5. Calculate your waist to height ratio.
6. Overweight and obesity management (NG246): Identifying and assessing overweight, obesity and central adiposity.
7. Overweight and obesity management (NG246): Rationale and impact.
8. Overweight and obesity management (NG246): Appendix A1 – Summary of evidence from surveillance.
9. Physical activity guidelines: UK Chief Medical Officers' report.
10. UK Chief Medical Officers' physical activity guidelines (full report).
11. Medicines regulator approves up to 7.2 mg dose of semaglutide (Wegovy) for patients with obesity.
12. First GLP-1 tablet for weight loss approved in the UK (oral semaglutide/Wegovy 25 mg tablets).
13. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
14. Tirzepatide.
15. UK first in Europe to authorise orforglipron (Foundayo) for weight management and type 2 diabetes.
16. New oral GLP-1 medicine for weight management and type 2 diabetes (Foundayo/orforglipron).
17. Orlistat.
18. Orlistat safety update.
19. Lean ME et al. Waist circumference as a measure for indicating need for weight management. BMJ. 1995.
20. Jayedi A et al. Aerobic Exercise and Weight Loss in Adults: A Systematic Review. 2024.
21. Ohkawara K et al. A dose-response relation between aerobic exercise and visceral fat reduction. 2007.
22. Impact of Different Exercise Modalities on Visceral Adipose Tissue in Normal Weight and Low-Overweight Individuals: A Systematic Review and Meta-Analysis. Biological Research for Nursing. 2025.
23. Unveiling the perfect workout: exercise modalities and dosages to combat visceral adipose tissue – systematic review with meta-analyses. Nutrition & Metabolism. 2025.
24. Mancini JG et al. Systematic Review of the Mediterranean Diet for Long-Term Weight Loss. 2016.
25. Shai I et al. Weight Loss with a Low-Carbohydrate, Mediterranean, or Low-Fat Diet. 2008.
26. Lifestyle-Induced Visceral Fat Loss as a Key Target for Durable Cardiometabolic Health. Circulation. 2025.
27. The efficacy of carbohydrate-restricted diets on reducing visceral and liver fat: systematic review and meta-analyses. Critical Reviews in Food Science and Nutrition. 2025.
28. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022.
29. Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. 2025.
30. Indirect comparative efficacy and safety of tirzepatide versus semaglutide for obesity in type 2 diabetes (SURMOUNT-2 and STEP 2). Diabetes, Obesity & Metabolism. 2025.

Frequently Asked Questions